Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial

• Main Authors: Pio López (Author), Eduardo López-Medina (Author), Xavier Sáez-Llorens (Author), Rodrigo deAntonio (Author), Taisei Masuda (Author), Paul M. Mendelman (Author), James Sherwood (Author), Frank Baehner (Author), Astrid Borkowski (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

We conducted a dose-finding phase 2 study of the HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) in two cohorts of children, 6-≤12 months and 1-≤4 years of age (N = 120 per cohort), in Panama and Colombia (ClinicalTrials.gov, identifier NCT02153112). On Day 1, children random...